Introduction {#Sec1}
============

Various data have indicated a consistent and strong association between early deep sedation and poor long-term outcomes, including mortality, cognitive decline and psychological complications \[[@CR1]--[@CR6]\]. A number of interventions have been suggested to address this \[[@CR7]--[@CR11]\], and a shift towards light sedation was strongly advocated in the Pain, Agitation and Delirium (PAD) guidelines \[[@CR12]\] and the recently published German Delirium, Analgesia, and Sedation guidelines \[[@CR13]\], but experience from recent controlled trials suggests that deep sedation continues to be commonplace in the intensive care unit (ICU) \[[@CR14], [@CR15]\].

We propose an integrated and adaptable approach to achieve light sedation, initiated early during an episode of critical illness and as a priority of care: ideally, patients should be comfortable, calm and able to cooperatively engage with caregivers and family at all times. This process is designed to deliver effective analgesia, titrated goal-directed minimal sedation and a patient-centred focus. To that end, this strategy may be conveyed in the mnemonic eCASH---early Comfort using Analgesia, minimal Sedatives and maximal Humane care. As illustrated in Fig. [1](#Fig1){ref-type="fig"}, eCASH has several distinct features:Fig. 1The eCASH concept: early implementation to manage and prevent pain, anxiety, agitation, delirium and immobility and facilitate patient-centred care. (\#Moderate or deep sedation remains relevant for some situations, including the management of severe respiratory failure with ventilator--patient dyssynchrony, prevention of awareness in patients receiving neuromuscular blocking agents, status epilepticus, surgical conditions necessitating strict immobilization and some cases of severe brain injury with intracranial hypertension)An emphasis on early implementation. The time component of eCASH is central to the concept.Generalizability: this is a sequential process-of-care intervention that can be delivered to all patients.Promotion and facilitation of patient-centred care.

This commentary assumes prior knowledge of the pharmacology of sedative and analgesic agents and familiarity with sedation, pain and delirium assessment scales and does not examine these matters in detail.

Heavy sedation: outdated but still used {#Sec2}
---------------------------------------

Profound sedation used to be widespread in ICU patients, not least because the mechanical ventilation of the era was considered to be otherwise intolerable \[[@CR16]\]. Significant improvements in ICU-related organ-support technology, such as advances in ventilator design, dialysis and extracorporeal circuits, have diminished that rationale for deep sedation and the PAD guidelines have identified the possibilities for improving clinical outcomes by achieving and maintaining light sedation \[[@CR12]\].

However, it is left to clinicians at the bedside to decide when to implement these measures. This often results in exactly the outcome they were meant to avoid: unnecessary deep sedation. This fallacy may be especially marked during the first few days in the ICU, when depth of sedation is considered---wrongly---not to be a critical consideration. In fact, observations from multiple studies suggest a consistent link between early deep sedation and significant harm \[[@CR1]--[@CR4]\], which may be attributed to a range of deleterious effects (Table [1](#Tab1){ref-type="table"}).Table 1Problems potentially associated with deep sedationLoss of human contactRespiratory depressionInactivity-induced diaphragm dysfunctionMyocardial depression and haemodynamic instabilityMicrovascular alterationsAltered gut function---ileusAirway (micro)aspirationIncreased risk of pneumoniaIncreased risk of thrombophlebitisRisk of decubitus ulcersDeliriumRisk of ICU-acquired weaknessPeripheral muscle weaknessImmunosuppressionProlonged mechanical ventilation/weaningProlonged ICU and hospital stayPermanent cognitive deficitsChronic psychological illnessesCosts

Moderate or deep sedation remains relevant for some situations, including the management of severe respiratory failure with ventilator--patient dyssynchrony, prevention of awareness in patients receiving neuromuscular blocking agents, status epilepticus, surgical conditions necessitating strict immobilization and some cases of severe brain injury with intracranial hypertension. For the vast majority of ICU patients, however, achieving and maintaining a light level of sedation should be sufficient and may avoid the potential harm caused by early oversedation. In this context, it should be noted that, given the evolution of sophisticated ventilator technologies \[[@CR17]\], the response to patient--ventilator asynchrony should firstly be efforts to identify a more tolerable ventilator setting and only subsequently an increased use of analgesics and/or sedatives. The ventilator should always be adapted to the patient, not the patient to the ventilator.

eCASH: a mnemonic for a modern approach {#Sec3}
---------------------------------------

Early comfort with minimal sedation should be provided as a clinical priority on a par with early resuscitation, early sepsis management and an early lung-protective ventilation strategy. eCASH, with its emphasis on comfort, analgesia, minimal sedation and patient-centred care, encompasses this new outlook. Implicit in eCASH is the understanding that if analgesia and light sedation do not achieve a calm and cooperative patient then the causes of failure should be identified and corrected before any resort to deep sedation is considered.

Pain management: the starting point for eCASH {#Sec4}
---------------------------------------------

Pain management with effective analgesia is the first priority in the implementation of the eCASH premise, and there is still ample scope for improvement in this area.

A systematic approach to anticipating individual patient requirements for analgesia is likely to improve pain management (Table [2](#Tab2){ref-type="table"}). Matters for consideration include pre-existing chronic pain syndromes (and associated medications) at admission and acute pain related to the presenting illness. During subsequent ICU care, analgesia is required for ongoing illness-related pain and discomfort related to routine treatments, such as suction and positioning. Intermittent increases in analgesia may also be required to address procedure-associated pain. (This requires appreciation of the pharmacokinetics of analgesics, especially the time-to-peak effect. Application of a nociceptive stimulation before the peak effect of the drug has been reached will give the impression that the analgesic is ineffective.) Regular evaluation and reassessment of analgesia requirements is therefore essential throughout the ICU stay.Table 2A suggested systematic approach to assessing likely analgesia requirements to manage pain in the ICUPain categoryExamplesPotential therapeutic approachesCandidate drugsPre-existing chronic pain or analgesia requirementsChronic neuropathic pain syndromesContinue chronic pain medications (e.g. gabapentin, amitriptyline)Gabapentin, amitriptylineOpioid addictionContinue or introduce long-acting agentsMethadoneConsider opioid-sparing agentsParacetamol (acetaminophen)Acute illness-related painMusculoskeletal traumaIntermittent or continuous opioid drugs, preferably PCAParacetamol (acetaminophen)SurgeryOpioid-sparing agentsKetamineVisceral and inflammation-related painAdjunct analgesicsDexmedetomidineAnalgo-sedative agentsContinuous ICU treatment-related pain/discomfortEndotracheal tube toleranceIntermittent or continuous opioidKetamineMechanical ventilationOpioid-sparing agentsDexmedetomidinePressure careAnalgo-sedative agentsPhysiotherapyJoint stiffnessIntermittent procedural painDrain insertionBoluses of opioidChest physiotherapyLocal anaesthesiaTracheostomy*NB* Non-steroidal anti-inflammatory agents should be used with extreme caution, if at all. Analgesic agents should *only* be used to achieve pain relief and not as sedatives. For procedural analgesia, deep sedation may be required*PCA* patient-controlled analgesia

In conscious, oriented patients a numeric rating scale (NRS) may be used to quantify pain \[[@CR18]\]. This is not viable if deep sedation is used or if communication is impeded by brain dysfunction; for such patients, validated pain assessment scales have been developed, such as the Behavioral Pain Scale (BPS) and the Critical-Care Pain Observation Tool (CPOT) \[[@CR19]--[@CR21]\].

Opioids remain central to analgesia and the needs of many patients may be satisfied with low-dose opioids. Patient-controlled analgesia (PCA) should be preferred for patients who are able to use it. eCASH, however, emphasises the need to reduce total opioid exposure in order to avoid adverse effects such as respiratory depression, feeding intolerance, constipation and ileus, withdrawal, tolerance, hyperalgesia, physical dependence and depression of the immune system. The use of an escalated multimodal strategy is recommended for that purpose (Fig. [2](#Fig2){ref-type="fig"}). For example, the use of paracetamol can reduce the overall opioid load and associated adverse effects \[[@CR22]\] and is feasible even in patients with hepatic impairment or injury. The introduction of adjunctive analgesics, such as pentins, lidocaine, alpha-2-agonists and low-dose ketamine, should be considered early if opioid needs are increasing. In the context of invasive mechanical ventilation, both ketamine and the alpha-2-agonists have been suggested to provide an opioid-sparing effect with a moderate sedative effect in patients who need both analgesia and sedation \[[@CR23], [@CR24]\].Fig. 2The eCASH implementation map commences upon ICU admission and focuses on coordinated effective analgesia and pain management and titrated minimal and light sedation. *Dashed double-headed arrows* identify factors and/or interventions that need to be considered concurrently. (\#Moderate and deep sedation remains relevant for specific clinical situations, as noted in Fig. [1](#Fig1){ref-type="fig"})

The emphasis on low ketamine dosage is important: the primary aim of ketamine use in this context should be to provide analgesia, and this is best achieved at low doses. Ketamine has sedative effects at higher doses but there is also a dose-dependent increase in side effects, notably psychosis, hallucination and delirium, that make it unsuitable for general use as a sedative agent.

Non-pharmacological measures, including music therapy and relaxation techniques, may be opioid-sparing and analgesia-enhancing \[[@CR25]\]. These interventions are safe according to the usual meaning of that term but they are not a reliable low-cost option, nor are they necessarily easy to provide.

Sedation in eCASH {#Sec5}
-----------------

Light sedation emphasises maintaining the patient in a state in which they are calm, comfortable and cooperative (the 3C rule). Ideally, the patient can be awake in order to maintain eye contact, interact with caregivers and family members and participate in physical and/or occupational therapy but permitted to drift off to sleep when uninterrupted. This state, broadly equivalent to a Richmond Agitation Sedation Scale (RASS) score of --1/0 \[[@CR26]\], has been linked with favourable effects on a range of clinical outcomes \[[@CR12]\].

Agitation in the critically ill patient can result from many factors, including pain, delirium, anxiety, drug withdrawal syndromes and discomfort resulting from poor ventilator synchrony, bowel dysfunction or pressure areas. Emphasis should be placed on diagnosing the cause of agitation rather than simply on treating the symptoms, which can result in unnecessary re-sedation. Suboptimal treatment of pain should also be considered as a major driver of agitation and treated diligently, with the emphasis on effective pain relief and not on masking signs of agitation. Attention must also be given to concomitant drivers of brain dysfunction, such as decreased cerebral perfusion, severe hypoxaemia, sepsis, high temperature, electrolyte imbalance, sleep disturbances and deliriogenic medications. Short-term sedation may be required while these precipitants are corrected. The presence or absence of delirium should be objectively tested by a validated tool, such as the Confusion Assessment Method for the ICU (CAM-ICU) \[[@CR27]\].

### Light or no sedation may be key to patient benefit {#Sec6}

Successful provision of light sedation requires a combination approach with attention being paid to the choice of sedative agent(s) as well as targeted and titrated sedative intensity. These considerations have influenced a general retreat from benzodiazepines as first-line sedatives in the ICU and a move towards short-acting, easy-to-titrate agents such as propofol and dexmedetomidine.

A pilot study of early goal-directed sedation illustrated successful implementation of targeted early light sedation using dexmedetom-idine as the primary sedative \[[@CR2]\]. Similarly, in a study comparing sedation with dexmedetomidine and midazolam for light sedation, sedation with dexmedetomidine was associated with lower rates of delirium, and shorter time on mechanical ventilation \[[@CR28]\]. Comparative studies of propofol and dexmedetomidine are equivocal \[[@CR29]\]; either agent may therefore be used when targeted light sedation is required.

A 'no-sedation' strategy has been reported by Strøm et al. \[[@CR11]\] to increase ventilator-free days, albeit with limitations such as increased risk of agitation. This approach uses morphine and haloperidol and there has to be some question regarding whether this is truly a 'no-sedative' regimen or rather an opioid-based sedation strategy. There is in addition a widespread (though untested) belief that successful implementation of this approach requires quite a high staff:patient ratio (typically 1:1). Nevertheless, these concepts and approaches are consistent with the eCASH philosophy, some specific aspects of which are now examined in more detail.

Detailed examination of the pharmacology of first-line sedatives is beyond the scope of this discussion, but it is noteworthy that investigation of electroencephalography (EEG) patterns in patients administered different drugs gives substance to the view that different mechanisms of action may give rise to qualitatively different and distinct forms of sedation \[[@CR30], [@CR31]\].

### Time to phase out benzodiazepines? {#Sec7}

It is premature to signal the elimination of benzodiazepines from the sedative repertoire but, as noted above, their place as first-line sedatives is greatly diminished in the eCASH paradigm. Non-benzodiazepine sedatives deliver better effects on some 'hard' outcomes, such as ICU length of stay and duration of mechanical ventilation (but not short-term mortality or delirium), than benzodiazepines, particularly in mechanically ventilated patients \[[@CR28], [@CR32]--[@CR35]\]. Benzodiazepines should be reserved for specific indications, such as amnesia for procedural sedation, convulsions, some instances of alcohol withdrawal, intractable agitation, palliation or severe brain pathologies. Whether or not intermittent, titrated application of predominantly anxiolytic gamma-aminobutyric acid (GABA)-agonists is beneficial is a matter of current research. When used, benzodiazepines should be titrated, preferably by intermittent rather than continuous infusion, which appears to be a risk factor for delirium \[[@CR36]\].

### Goodbye daily sedation stops: hello frequent titration protocols {#Sec8}

The use of bedside sedation scales may move the ICU team away from deep and prolonged sedation (often based on use of benzodiazepines) towards continuous targeted light sedation with drugs that are relatively short-acting and easier to titrate. This will likely diminish the role and need for daily sedation stops as originally conceived and implemented, and is in accordance with the 3C principle already outlined.

Where sedation is required for optimizing patient care, sedative medications should be titrated to the lowest amount required to achieve the target sedation level deemed necessary. The medical team should constantly evaluate the need for ongoing sedation and down-titrate sedative medications, with the explicit goal of complete withdrawal at the earliest clinically warranted opportunity. Sedative and analgesic drugs may accumulate in critically ill patients despite careful titration and use of short-acting agents. A stage may be reached when sedation stops may be needed only in cases where drug accumulation is suspected. There is now reasonable evidence attesting to the positive impact of protocol use on standards of care in analgesia, sedation and delirium \[[@CR37]--[@CR41]\], although not all the data are conclusive and affirmative \[[@CR42], [@CR43]\]. It should be noted that the evidence for protocolized therapy derives substantially from studies of benzodiazepines \[[@CR40]\] and that no firm conclusions on the impact of protocolization may be drawn for other agents. As Minhas et al. \[[@CR40]\] have noted, explanations of the benefit seen with protocolization are likely to involve more than simply a reduction in total sedative use.

### Validated sedation scales at the bedside: subjective but valuable {#Sec9}

Checking for excess sedation and analgesia should be part of a routine bedside evaluation by nurses, like adequate feeding, having the bed elevated or applying thromboembolism prophylaxis \[[@CR44]\].

The use of clinically validated scales to monitor sedation level is often recommended to facilitate targeted, goal-directed sedation and improve communication among care providers. Sedation scales rely on an interaction between patient and caregiver and it may be argued that they lead to confirmation bias, i.e., to confirming a level of sedation already presumed to have been achieved. Nevertheless, they yield a quantitative estimate of sedation depth that can be questioned and scrutinised and that may be particularly useful in patients with deep sedative states.

The development of objective and reliable neurophysiologic measures of sedation level, while proceeding at an experimental and proof-of-concept level, is still far from being a practical option at the bedside. A major problem with currently available systems, which were mostly designed for depth of anaesthesia monitoring, is the confounding effect of facial electromyography on EEG-based algorithms \[[@CR45], [@CR46]\]. The use of neurophysiologic monitors should, however, be considered in patients requiring deeper sedation to avoid a descent into profound sedation.

Patient-centred care, a core component of eCASH {#Sec10}
-----------------------------------------------

The concept of eCASH is pivotal to the delivery of patient-centred care for ICU patients (Table [3](#Tab3){ref-type="table"}). A programme that addresses all these elements should be implemented on ICU admission and continued throughout the ICU stay. Close attention should be given to identifying and mitigating factors that obstruct the early introduction of eCASH.Table 3Components of patient-centred careFrequent and appropriate communicationExplanations of the care componentsTime and space orientationNoise reductionAvoidance of unnecessary restraintsSleep promotion at nightPhysical activity/early mobilizationMental stimulationOccupational therapy including cognitive trainingFamily engagement

Interdisciplinary collaboration is essential to the implementation and delivery of the eCASH premise. The team culture should focus on avoiding potentially harmful interventions and promoting best practice at all times. The role of bedside nurses and caregivers is pivotal within this framework, and adequate staff education programmes specific to sedation--analgesia management should be a core activity and competency \[[@CR47], [@CR48]\]. Although nurse:patient ratios differ between hospitals and may be regarded as suboptimal in many cases, inappropriately deep sedation is not a defensible response to staff shortages. In this context, it should be noted that intervention consistent with the eCASH philosophy was associated with less use of physical restraints in the pilot phase of a controlled trial in mechanically ventilated, critically ill patients \[[@CR49]\]. These data provide some assurance that a general presumption towards light sedation need not be accompanied by greater need for physical restraints where nursing ratios are less than ideal.

Some matters for consideration are discussed in the next part of this commentary; additional local factors will apply in different ICUs.

### Promotion of sleep {#Sec11}

Many patients' experience of sleep in an ICU is unsatisfactory and potentially disadvantageous, and poor sleep has been identified in some studies as a prelude to and risk factor for delirium \[[@CR50], [@CR51]\]. Restoration of more normal sleep may become a therapeutic goal in the ICU, though whether that is a benefit in its own right or a surrogate for other changes is difficult to determine at present \[[@CR52]\].

There is evidence that, beyond discomfort, sleep deprivation/alteration is associated with immunodepressive effects that may be clinically relevant \[[@CR53], [@CR54]\]. These data provide an incentive to prevent/correct sleep disturbance in ICU patients, albeit that formal studies of the effects of correction are not available. These reflections also focus attention on differential effects of sedatives on immune function \[[@CR54], [@CR55]\].

Improving patient sleep can be justified as a quality-of-care issue, with non-pharmacological methods representing a natural starting point. The deployment of 'sleep bundles'---which include maintenance of regular sleep--wake rhythms, reduction in night-time light, noise and care episodes and use of earplugs and music---may be helpful \[[@CR25], [@CR56], [@CR57]\]. Too little is known about the effect of analgesics and various sedative agents on sleep patterns in the ICU \[[@CR58]\]. The value of adjunct therapies, such as melatonin or tryptophan, is unclear \[[@CR59], [@CR60]\].

### Early mobilization strategies {#Sec12}

An important corollary of the eCASH strategy is that the patient is capable of involvement in programmes for early mental stimulation and physical activity. The benefits of early mobilization for adult ICU patients have been documented \[[@CR61]--[@CR64]\]; this may help to avoid agitation, delirium and ICU-acquired weakness and hence contributes to the eCASH paradigm \[[@CR63], [@CR64]\]. The risks of early mobilization appear to be smaller than might have been anticipated and the barriers to implementation, although impossible to ignore, are surmountable \[[@CR65], [@CR66]\]. It is therefore a matter of concern that outmoded approaches to sedation still appear to be a significant impediment to early mobilization \[[@CR67], [@CR68]\].

### Communication with staff/relatives {#Sec13}

Sedation strategy can significantly influence patients' communication with staff/relatives. Patients' experiences of interaction with ICU staff are often brief and fragmented and the effects of those contacts can be incomprehensible, confusing or alarming to the patient \[[@CR69]\]. Clearly, the capacity of a patient to communicate and understand is linked to alertness: to that extent, the adoption of eCASH-style light sedation may be expected to benefit the patient. Conversely, enhancement of the patient's capacity to interact will benefit the patient only if staff are responsive to what the patient communicates and able to respond in a way that is coherent and comprehensible to the patient. Various training and technical measures to enhance the quality of communication have been proposed \[[@CR70]\]. Good communication---an inherent theme of eCASH---may be expected to decrease the need for physical restraints.

Reorientation can be promoted through simple measures such as return of hearing aids and spectacles and other measures that allow patients to re-establish meaningful contacts with their surroundings and with other people. Review of the visiting hours policy is an integral part of this aspect of care and rehabilitation. Attention to the needs of relatives is also relevant both for its effects on patients and as a quality improvement goal in its own right \[[@CR71]\].

eCASH is about patients, their carers and families {#Sec14}
--------------------------------------------------

Full realization of the goals of eCASH requires changes to the process and culture of care. Successful implementation of change requires a close interdisciplinary and interprofessional collaboration and consideration of the different interests and priorities of the participating healthcare specialists \[[@CR72]\].

The focus must be on multimodal interventions, some of which will very likely fall outside the scope of what might usually be described as 'medical' \[[@CR73]\]. Promoting factors include implementation planning, training/support and effective documentation, and perhaps debriefing, whereas excessive staff turnover, poor staff morale and lack of interdisciplinary respect are obstacles to implementation \[[@CR72]\]. The development of robust systems to track and feed back the quality of sedation and analgesia provides potential methods for driving quality improvement in a manner similar to the successful programmes that have decreased infections in ICUs \[[@CR74]\].

Transferring responsibility and ownership of sedation management to bedside staff requires appropriate training and education programmes within ICUs. Clear strategies to manage the causes of agitation are needed to ensure 'buy-in' from nursing teams, with access to support and advice for difficult cases. A supportive and 'no-blame' culture in relation to the identification and review of sedation-related adverse events is a key element in the implementation of nurse-led management.

Given the variety of circumstances encountered in ICUs, it is not feasible to offer detailed prescriptions for how to implement change. By extension, it is not possible to make claims for how much money (if any) might be saved by the full and successful implementation of such a formula. That, however, is to miss the point: eCASH is a process for optimising clinical benefit to patients, both during their time in the ICU and potentially beyond it; that goal is worthwhile in its own right.

Developing eCASH {#Sec15}
----------------

The guiding principles of eCASH are clear and components of the eCASH concept are supported by current guidelines; details of this philosophy of care can be expected to evolve in response to clinical trial data. Among trials currently in progress that may be expected to influence the final form of eCASH are: SPICE III (NCT01728558); MENDS II (NCT01739933); NONSEDA (NCT0196768); AWARE (NCT01617265); DESIRE (NCT01760967); and VITALITY (NCT02143661), which examines environmental influences on ICU outcomes. A longer-term goal would be to evaluate the clinical effectiveness of a prespecified eCASH bundle in a randomised clinical trial.

**Take-home message:**

Excessive deep sedation, even if restricted to initiation of ICU treatment, is associated with worse outcome for ICU patients: everything should be done to avoid it. We propose a new approach with the acronym eCASH---early Comfort using Analgesia, minimal Sedatives and maximal Humane care---predicated on the early achievement of pain relief and the maintenance of comfort with minimal sedation being used to facilitate natural sleep, early mobilization and engagement with caregivers and relatives.
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